All Posts

A Deep Dive into Brain-Computer Interfaces: The US$400 Billion Industry

Jul 1, 2026

•

7 min read

A Closer Look at the ASX Supervision Report

Jun 30, 2026

•

6 min read

Acid Test: Definium’s Positive Phase 3 LSD Readout

Jun 29, 2026

•

4 min read

Is Medtech Back?

Jun 26, 2026

•

3 min read

My Third Armchair Pick: Control Bionics (ASX: CBL)

Jun 25, 2026

•

13 min read

Avecho’s (AVE) Phase 3 Insomnia Result Awakens Biotech Market

Jun 24, 2026

•

4 min read

Fighting over the shrinking pie

Jun 23, 2026

•

9 min read

No Pain, No Gain: The Paradigm Story (ASX: PAR)

Jun 22, 2026

•

9 min read

Tax On, Tax Off: What new changes mean for biotech

Jun 19, 2026

•

4 min read

Catalyst Munting: Cynata (CYP) Trial Pulls up Short

Jun 18, 2026

•

4 min read

Fireside Conversation with Emyria

Jun 17, 2026

•

4 min read

Catalyst Hunting: The Actinogen Story (ASX: ACW)

Jun 16, 2026

•

10 min read

1 2 3 4...13

All Posts

A Deep Dive into Brain-Computer Interfaces: The US$400 Billion Industry

A Closer Look at the ASX Supervision Report

Acid Test: Definium’s Positive Phase 3 LSD Readout

Is Medtech Back?

My Third Armchair Pick: Control Bionics (ASX: CBL)

Avecho’s (AVE) Phase 3 Insomnia Result Awakens Biotech Market

Fighting over the shrinking pie

No Pain, No Gain: The Paradigm Story (ASX: PAR)

Tax On, Tax Off: What new changes mean for biotech

Catalyst Munting: Cynata (CYP) Trial Pulls up Short

Fireside Conversation with Emyria

Catalyst Hunting: The Actinogen Story (ASX: ACW)

The Armchair Analyst